AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field
Fierce Pharma
NOVEMBER 30, 2023
The sizzling antibody-drug conjugate (ADC) field is at the center of another major life sciences deal. | The sizzling antibody-drug conjugate field is at the center of another major life sciences deal. Hoping to redeem itself following the epic Rova-T failure, AbbVie is shelling out $10.1
Let's personalize your content